<DOC>
	<DOCNO>NCT02166814</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination Fimasartan/Rosuvastatin comparison component administer alone patient essential hypertension dyslipidemia .</brief_summary>
	<brief_title>A Randomized , Double-blind , Multicenter , Phase III Study Evaluate Efficacy Safety Combination Fimasartan/Rosuvastatin Comparison Each Component Administered Alone Patients With Essential Hypertension Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Patients voluntarily sign informed consent participate clinical trial 2 . Male female 20 75 year old 3 . Patients must confirm essential hypertension dyslipidemia Screening visit ( Visit1 ) 4 . Patients meet follow criterion fast LDLC blood pressure Baseline visit ( Visit3 ) assessment undergo therapeutic lifestyle change . Low risk group : case risk factor apart hypertension / LDLC ( mg/dL ) : ≥160 , ≤250 , Mean SiSBP ( mmHg ) : ≥140 , &lt; 180 Moderate risk group : case equal one risk factor apart hypertension 10year risk less 10 % / LDLC ( mg/dL ) : ≥160 , ≤250 , Mean SiSBP ( mmHg ) : ≥140 , &lt; 180 Moderate high risk group : case equal one risk factor apart hypertension 10year risk 10 % 20 % / LDLC ( mg/dL ) : ≥130 , ≤250 , Mean SiSBP ( mmHg ) : ≥140 , &lt; 180 High risk group : case CHD ( Coronary heart disease ) CHD risk equivalent Risk factor include cigarette smoking , hypertension ( BP≥140/90 mmHg antihypertensive medication ) , low HDL cholesterol ( &lt; 40mg/dL ) , family history premature CHD ( CHD male firstdegree relative &lt; 55 year age ; CHD female firstdegree relative &lt; 65 year age ) , age ( men≥45 year ; woman ≥55 year ) . case HDLC ≥60mg/dL , reduce 1 total number risk factor . Electronic 10 year risk calculator available www.nhlbi.nih.gov/guidelines/cholesterol CHD include history myocardial infarction , unstable angina , coronary artery procedure ( angioplasty bypass surgery ) , evidence clinically significant myocardial ischemia . CHD risk equivalent include atherosclerotic disease ( peripheral arterial disease , abdominal aortic aneurysm carotid artery disease [ transient ischemic attack stroke carotid origin &gt; 50 % obstruction carotid artery ] ) , diabetes 2+ risk factor 10 year risk 20 % 5 . Subject must able understand trial procedure willing cooperate complete trial . 1 . Severe hypertension patient mean siSBP ≥ 180mmHg and/or SiDBP ≥110mmHg assessment Screening visit ( Visit1 ) and/or Baseline visit ( Visit3 ) . Or patient postural hypotension manifestation . 2 . Patients mean SiSBP 3 time measurement 20mmHg . 3 . Secondary hypertension patient , limit follow disease ( example : renovascular disease , adrenal medullary cortical hyperfunctions , coarctation aorta , hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing 's syndrome , pheochromocytoma , polycystic kidney disease , etc ) 4 . Secondary dyslipidemia : nephrotic syndrome , dysproteinemia , obstructive hepatopathy Cushing 's syndrome . 5 . Patients fast TG ≥ 400mg/dL PreBaseline visit ( Visit2 ) assessment 6 . History myopathy , rhabdomyolysis or/and CK ≥ 2 time upper normal limit . 7 . Use lipid modify drug within 4 week prior PreBaseline visit ( Visit2 ) and/or antihypertensive drug within 2 week prior PreBaseline visit ( Visit2 ) 8 . Clinically significant renal function abnormality laboratory result PreBaseline visit ( i.e . serum creatinine ≥ 1.5 time upper normal limit ) , liver function abnormality ( ALT , AST ≥ 2 time upper normal limit ) , severe fatty liver disease require medication . 9 . Clinically significant hypokalemia ( le 3.5 mmol/L ) hyperkalemia ( exceed 5.5 mmol/L ) measure PreBaseline visit ( Visit2 ) 10 . Subjects follow surgical internal disease may affect absorption , distribution , metabolism excretion drug condition include follow ( limited ) : history major gastrointestinal surgery include gastrectomy , gastroenterostomy bowel resection , gastrointestinal bypass graft stabling ; current active gastritis , ulcer , gastrointestinal rectal bleeding , presence active inflammatory bowel syndrome biliary obstruction past 12 month . 11 . Subjects depletion body fluid sodium ion able correct 12 . Subjects sever insulindependent Diabetes Mellitus ( DM ) Chronic DM ( HbA1c &gt; 9 % PreBaseline visit , dosage oral hypoglycemic agent modify within 12 week prior screen visit , currently use active insulin treatment ) hypothyroidism able correct . ( TSH ≥ 1.5 time upper normal limit ) 13 . Subjects severe heart disease ( Heart failure New York Heart Association ( NYHA ) class 3 4 ) , history following within past 6 month ; ischemic heart disease ( e.g . angina pectoris , myocardial infarction ) , peripheral vascular disease , percutaneous transluminal coronary angioplasty , coronary artery bypass graft . 14 . Subjects clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinical significant arrhythmia condition discretion investigator 15 . Subjects hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant aortic valve stenosis , mitral valve stenosis . 16 . Subjects severe cerebrovascular disorder ( e.g . stroke , cerebral infarction cerebral hemorrhage within past 6 month ) 17 . Subjects chronic inflammatory disease require chronic antiinflammatory therapy , past current medical history waste disease , autoimmune disease ( e.g . rheumatoid arthritis , systemic lupus erythematosus ) connective tissue disease . 18 . Subjects know moderate malignant retinosis ( e.g . retinal hemorrhage , visual disturbance retinal microaneurysm past 6 month ) 19 . Subjects hepatitis B ( include positive test HBsAg ) , hepatitis Cpositive 20 . Subjects history evidence abuse drug alcohol within past 2 year . 21 . Medical history hypersensitivity angiotensin II antagonist base drug HMGCoA reductase inhibitor base drug ingredient contain 2 drug . 22 . Medical history clinically significant hypersensitivity component drug investigational product additive ( yellow 5 ) 23 . Subjects hereditary disorder galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . 24 . Pregnant woman lactate female . 25 . Subjects plan pregnancy childbearing potential use effective contraceptive method ( surgical sterilize , intrauterine ( contraceptive ) device/condom combination diaphragm spermicidal agent ) 26 . Subjects participate another trial take investigational product within 12 week prior Screening visit 27 . Medical history kind malignant tumor include leukemia lymphoma past 5 year 28 . A subject reason specify , ineligible participate clinical trial discretion study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>